Around one-third of patients with juvenile arthritis fail to respond to first-line treatments

help for juvenile  arthritis

When treating the symptoms of juvenile idiopathic arthritis, also called juvenile idiopathic arthritis (JIA), disease-modifying anti-rheumatic drugs (DMARDs) and anti-tumor necrosis factor (TNF) are often used. These include methotrexate (MTX), Enbrel and Humira.

Around one-third of patients with juvenile idiopathic arthritis fail to respond to MTX or TNF therapy. Even fewer achieve the American College of Rheumatology Pediatric 70% criteria for response.

In this new research, printed in The Journal of Rheumatology in January 2018, the researchers evaluated whether measuring blood levels of the protein S100A12 could be a suitable predictor for treatment outcomes in JIA patients.
Because change in serum S100-protein myeloid-related protein complex 8/14 (MRP8/14) is associated with therapeutic response, we tested granulocyte-specific S100-protein S100A12 as a potential biomarker for treatment response.
S100A12 serum concentration was determined by ELISA in 163 patients treated with MTX or anti-TNF at baseline and follow up. Treatment response achievement of inactive disease, and improvement in Juvenile Arthritis Disease Activity Score were recorded. ELISA is enzyme-linked immunosorbent assay - a test that uses antibodies and color change to identify a substance. 

Researchers found that when compared to non-responders, patients who responded to the administrated therapies had significantly higher baseline levels of blood S100A12.

People who will respond to MTX or anti-TNF treatment can be identified by pre-treatment S100A12 serum concentration levels.

drugs for juvenile arthritis


S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis

Faekah GoharJanneke AninkHalima MoncrieffeLisette W.A. Van Suijlekom-Smit
Femke H.M. PrinceMarion A.J. van RossumKoert M. DolmanEsther P.A.H. Hoppenreijs
Rebecca ten CateSimona UrsuLucy R. WedderburnGerd HorneffMichael Frosch
Dirk Foell and Dirk Holzinger

No comments: